N: Sorry, but you don't seem to really get it. Yes, the results are old - that is what a review is about...

This recent example of recognition of Apabetalone trial results by an article in a journal with a high impact factor (https://www.nature.com/sigtrans/about) is new. The authors are from a university in Texas - apparently not affiliated with Resverlogix in any way, shape or form - not employees, not investigators not nothing. That too is relevant to note.

The notion in academic circles that RVX208-trial results indicated that RVX208 is effective in CAD patients is gaining traction. Nice to see.

BP listens to academia (often hired as consultants) in case you wonder.

BR.

BKC